{"title":"Perspektiven der Erhaltungstherapie beim Ovarialkarzinom","authors":"Friederike Klein","doi":"10.1055/a-2092-7867","DOIUrl":"https://doi.org/10.1055/a-2092-7867","url":null,"abstract":"Beim fortgeschrittenen Ovarialkarzinom spielt die Erhaltungstherapie nach Ansprechen auf eine Standardchemotherapie mit Carboplatin und Paclitaxel eine immer wichtigere Rolle. Eingesetzt werden bislang Bevacizumab und PARP-Inhibitoren. Studien zu weiteren Konzepten laufen.","PeriodicalId":474444,"journal":{"name":"Onkologische Welt","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134917777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hepatozelluläres Karzinom","authors":"Katharina Arnheim","doi":"10.1055/a-2127-7093","DOIUrl":"https://doi.org/10.1055/a-2127-7093","url":null,"abstract":"Patienten mit hepatozelluärem Karzinom (HCC) und hohem Rezidivrisko nach Resektion oder Ablation profitieren von der adjuvanten Therapie mit Atezolizumab plus Bevacizumab. Erreicht wird eine signifikante Reduktion des Rezidivrisikos ohne Einschränkung der Lebensqualität.","PeriodicalId":474444,"journal":{"name":"Onkologische Welt","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134918329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Multiples Myelom","authors":"Reimund Freye","doi":"10.1055/a-2120-6426","DOIUrl":"https://doi.org/10.1055/a-2120-6426","url":null,"abstract":"Auf dem diesjährigen Kongress der European Hematology Association (EHA) thematisierte Dr. Amrita Krishnan, Duarte (USA), neue Medikamente für das rezidivierende/refraktäre Multiple Myelom (r/r MM). Wenn eine autologe Stammzelltransplantation nicht möglich ist, stehen Kombinationen aus Proteasom-Inhibitoren (PI), Immunmodulatoren (iMiD) und Dexamethason zur Verfügung, ergänzt durch Zugabe eines CD38-Antikörpers.","PeriodicalId":474444,"journal":{"name":"Onkologische Welt","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134917785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Operables Magenkarzinom","authors":"Katharina Arnheim","doi":"10.1055/a-2127-7121","DOIUrl":"https://doi.org/10.1055/a-2127-7121","url":null,"abstract":"Die Phase-III-Studie ATTRACTION-5 beim operablen Magenkarzinom ging negativ aus: Bei Addition von Nivolumab zur adjuvanten Chemotherapie wurde keine Senkung des Rezidivrisikos erreicht.","PeriodicalId":474444,"journal":{"name":"Onkologische Welt","volume":"122 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134918552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Real-World-Daten zum NSCLC","authors":"Katharina Arnheim","doi":"10.1055/a-2127-6903","DOIUrl":"https://doi.org/10.1055/a-2127-6903","url":null,"abstract":"Bei älteren Patienten mit nicht-kleinzelligem Lungenkarzinom (NSCLC) sind die Immunchemotherapie und die alleinige Immuntherapie in der ersten Linie vergleichbar effektiv. Allerdings induziert die Immunchemotherapie mehr Toxizitäten, sodass die alleinige Immuntherapie mit Checkpoint-Inhibitioren (CPI) zu bevorzugen ist.","PeriodicalId":474444,"journal":{"name":"Onkologische Welt","volume":"199 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134917519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Resektables NSCLC","authors":"Katharina Arnheim","doi":"10.1055/a-2127-6856","DOIUrl":"https://doi.org/10.1055/a-2127-6856","url":null,"abstract":"Mittlerweile sind synergistische Effekte bei Kombination von Immuntherapie und Angiogenesehemmung in der Behandlung des nicht-kleinzelligen Lungenkarzinoms (NSCLC) bekannt. Das bestätigt die Phase-III-Studie EAST ENERGY, in der das Regime Pembrolizumab/Ramucirumab zu einer hohen Rate pathologischer Remissionen und R0-Resektionen führte.","PeriodicalId":474444,"journal":{"name":"Onkologische Welt","volume":"137 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134918576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Fortgeschrittenes Nierenzellkarzinom","authors":"Katharina Arnheim","doi":"10.1055/a-2066-5731","DOIUrl":"https://doi.org/10.1055/a-2066-5731","url":null,"abstract":"In der Erstlinientherapie des metastasierten Nierenzellkarzinoms (RCC) sind immunonkologische (IO) Kombinationen und Regime mit einem Checkpoint-Inhibitor (CPI) plus Tyrosinkinase-Inhibitor (TKI) heute leitlinienkonformer Standard. Vorteile der TKI/IO-Regime sind die geringe primäre Progressionsrate und die hohen Responseraten.","PeriodicalId":474444,"journal":{"name":"Onkologische Welt","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134951197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Palliativmedizin","authors":"Martina Eimer","doi":"10.1055/a-2089-9288","DOIUrl":"https://doi.org/10.1055/a-2089-9288","url":null,"abstract":"Opioide sind für den Einsatz starker Schmerzen zugelassen, jedoch sollten Opioide nicht unkritisch indiziert werden. Das gilt auch nach Ansicht der Experten für den Einsatz von Cannabis beim Symposium „State of the Art-Betäubungsmittel in der Palliativmedizin“ im Rahmen des 63. Kongresses der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP).","PeriodicalId":474444,"journal":{"name":"Onkologische Welt","volume":"83 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134951196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Metastasiertes Prostatakarzinom","authors":"Ine Schmale","doi":"10.1055/a-2050-5800","DOIUrl":"https://doi.org/10.1055/a-2050-5800","url":null,"abstract":"Mehr als 5800 Teilnehmern konnte die American Society of Clinical Oncology (ASCO) beim Genitourinary Cancers Symposium in San Francisco sowie online begrüßen und ein hochkarätiges Programm bieten. Unter den zahlreichen Studiendaten wurden auch Ergebnisse präsentiert, die neue Therapiestandards beim Prostatakarzinom definieren oder bestätigen.","PeriodicalId":474444,"journal":{"name":"Onkologische Welt","volume":"138 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136338606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
求助内容：
应助结果提醒方式：